Associated Papers
The Genetic Landscape of Acute Necrotizing Encephalopathy: Insights Into the Possible Pathogenesis.
Geng C et al.
Journal of Clinical Neurology (seoul, Korea), 2025
40635539 (PubMed )
Supplement: jcn-21-340-s001.pdf
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
39991480 (PubMed )
Supplement: mmc5.xlsx › Sheet1
Population-specific putative causal variants shape quantitative traits.
Koyama S et al.
Nature Genetics, 2024
39363016 (PubMed )
Supplement: 41588_2024_1913_MOESM3_ESM.xlsx › ST8_Missense_PPI___0.1
Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG et al.
Cancer Drug Resistance (alhambra, Calif.), 2024
Identification of Genetic Predisposition in Noncirrhotic Portal Hypertension Patients With Multiple Renal Cysts by Integrated Analysis of Whole-Genome and Single-Cell RNA Sequencing.
Wu Y et al.
Frontiers in Genetics, 2021
34868264 (PubMed )
Supplement: Table2.XLSX › Sheet1
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
Exome sequencing identifies SLC26A4, GJB2, SCARB2 and DUOX2 mutations in 2 siblings with Pendred syndrome in a Malaysian family.
Chow YP et al.
Orphanet Journal of Rare Diseases, 2017
28222800 (PubMed )
Supplement: 13023_2017_575_MOESM3_ESM.xlsx › Table_S2
Lack of genomic diversity in the SLC47A1 gene within the indigenous Xhosa population.
Jacobs C et al.
Drug Metabolism and Personalized Therapy, 2016
Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.
Yoon H et al.
The Aaps Journal, 2013
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
Mannino GC et al.
Molecular Diagnosis & Therapy, 2012
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function.
Chen Y et al.
The Pharmacogenomics Journal, 2009
Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity.
Kajiwara M et al.
Journal of Human Genetics, 2009
Select a paper to view details